<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02874404</url>
  </required_header>
  <id_info>
    <org_study_id>345-16</org_study_id>
    <secondary_id>NCI-2016-01082</secondary_id>
    <secondary_id>345-16</secondary_id>
    <secondary_id>P30CA036727</secondary_id>
    <nct_id>NCT02874404</nct_id>
  </id_info>
  <brief_title>TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma</brief_title>
  <official_title>A Single-Center Phase IIa Study Evaluating the Safety and Tolerability of TGR-1202 and Ibrutinib in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Trial of the Lymphoma Precision Medicine Laboratory</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Matthew Lunning, DO</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Nebraska</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase IIa trial studies the side effects and how well TGR-1202 and ibrutinib work in&#xD;
      treating patients with diffuse large B-cell lymphoma that has returned after a period of&#xD;
      improvement or does not respond to treatment. TGR-1202 and ibrutinib may stop the growth of&#xD;
      cancer cells by blocking some of the enzymes needed for cell growth.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the safety and tolerability of PI3K delta inhibitor TGR-1202 (TGR-1202) and&#xD;
      ibrutinib in relapsed and refractory (rel/ref) diffuse large B-cell lymphoma (DLBCL).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the overall response rate (ORR) defined as the sum of complete responses (CR)&#xD;
      and partial responses (PR).&#xD;
&#xD;
      II. To determine the event-free survival (EFS), time to response (TTR), and duration of&#xD;
      response (DOR) in patients with rel/ref DLBCL.&#xD;
&#xD;
      TERTIARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate molecular profiling of patient samples (optional lymph node biopsies) obtained&#xD;
      at days 0 (pre-treatment; core biopsy), day 8 (fine needle aspiration) and end of treatment&#xD;
      (progressive disease or end of study treatment-1 year; core biopsy).&#xD;
&#xD;
      II. To evaluate the baseline characteristics and dynamic shifts in mutational Landscape,&#xD;
      transcriptional signatures and intracellular signaling cascades in primary tumor cells.&#xD;
&#xD;
      III. To define the mutational status of 384 genes that mutated in DLBCL, including cluster of&#xD;
      differentiation (CD)79B, caspase recruitment domain family member 11 (CARD11), and myeloid&#xD;
      differentiation primary response 88 (MYD88).&#xD;
&#xD;
      IV. To evaluate signatures of B-cell receptor signaling and the back-up pathway of oxidative&#xD;
      phosphorylation.&#xD;
&#xD;
      V. To measure the basal and induced level of activation of components within parallel&#xD;
      signaling pathways downstream of the B-cell receptor.&#xD;
&#xD;
      VI. To monitor changes in T-cell characteristics in response to exposure to TGR-1202 and&#xD;
      ibrutinib.&#xD;
&#xD;
      VII. To perform quantitative response evaluation by peripheral blood cell-free&#xD;
      deoxyribonucleic acid (DNA) sequencing at enrollment, day 8, 1 month, at every response&#xD;
      assessment time point compared to standard radiographic response evaluation by positron&#xD;
      emission tomography (PET)/ computed tomography (CT) or CT and end of treatment (progressive&#xD;
      disease or end of study treatment-1 year).&#xD;
&#xD;
      VIII. To evaluate the genetic profiling for drug resistance mutations. IX. To evaluate DLBCL&#xD;
      subtype analysis by immunohistochemistry compared to Nanostring assessment.&#xD;
&#xD;
      OUTLINE: Patients are assigned to 1 of 3 groups.&#xD;
&#xD;
      GROUP A: Patients receive PI3K delta inhibitor TGR-1202 orally (PO) once daily (QD) on days&#xD;
      1-28 and ibrutinib PO QD on days 9-28 of course 1 and days 1-28 of subsequent courses.&#xD;
      Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      GROUP B: Patients receive ibrutinib PO QD on days 1-28 and PI3K delta inhibitor TGR-1202 PO&#xD;
      QD and days 9-28 of course 1 and days 1-28 of subsequent courses. Treatment repeats every 28&#xD;
      days for up to 12 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      GROUP C: Patients then receive PI3K delta inhibitor TGR-1202 PO QD and ibrutinib PO QD on&#xD;
      days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up for 30 days and after 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Actual">July 1, 2019</completion_date>
  <primary_completion_date type="Actual">July 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Adverse Events Assessed Using NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03</measure>
    <time_frame>Up to 112 days (course 4)</time_frame>
    <description>Notable serious or recurrent adverse events (SAEs or AEs) of interest occurring across all cycles regardless of attribution</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>ORR is defined as number of patients achieving a best response of complete response or partial response at any disease assessment time point. Response is based on PET/CT (Deauville 3 or less) or CT alone if CR is achieved by PET/CT. Response criteria, modified from the Lugano response criteria. DLBCL is considered FDG avid.&#xD;
Complete response:&#xD;
Complete disappearance of all detectable clinical evidence of disease and definitely disease-related symptoms if present before therapy.&#xD;
Criteria for Partial Response (PR):&#xD;
Regression of measurable disease and no new sites</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Progression-free Survival (PFS) at 6 Months</measure>
    <time_frame>Time between study registration and documented progression or death if no progression was observed, assessed up to 4 years (6 Month estimate shown)</time_frame>
    <description>PFS is defined as the time between study registration and documented progression or death if no progression was observed.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Recurrent Diffuse Large B-Cell Lymphoma</condition>
  <condition>Refractory Diffuse Large B-Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Group A (PI3K delta inhibitor TGR-1202, ibrutinib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive PI3K delta inhibitor TGR-1202 PO QD on days 1-28 and ibrutinib PO QD on days 9-28 of course 1 and days 1-28 of subsequent courses. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B (Ibrutinib, PI3K delta inhibitor TGR-1202)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive ibrutinib PO QD on days 1-28 and PI3K delta inhibitor TGR-1202 PO QD and days 9-28 of course 1 and days 1-28 of subsequent courses. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C (PI3K delta inhibitor TGR-1202, ibrutinib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients then receive PI3K delta inhibitor TGR-1202 PO QD and ibrutinib PO QD on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Group A (PI3K delta inhibitor TGR-1202, ibrutinib)</arm_group_label>
    <arm_group_label>Group B (Ibrutinib, PI3K delta inhibitor TGR-1202)</arm_group_label>
    <arm_group_label>Group C (PI3K delta inhibitor TGR-1202, ibrutinib)</arm_group_label>
    <other_name>BTK Inhibitor PCI-32765</other_name>
    <other_name>CRA-032765</other_name>
    <other_name>Imbruvica</other_name>
    <other_name>PCI-32765</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative markers</description>
    <arm_group_label>Group A (PI3K delta inhibitor TGR-1202, ibrutinib)</arm_group_label>
    <arm_group_label>Group B (Ibrutinib, PI3K delta inhibitor TGR-1202)</arm_group_label>
    <arm_group_label>Group C (PI3K delta inhibitor TGR-1202, ibrutinib)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PI3K-delta Inhibitor TGR-1202</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Group A (PI3K delta inhibitor TGR-1202, ibrutinib)</arm_group_label>
    <arm_group_label>Group B (Ibrutinib, PI3K delta inhibitor TGR-1202)</arm_group_label>
    <arm_group_label>Group C (PI3K delta inhibitor TGR-1202, ibrutinib)</arm_group_label>
    <other_name>RP5264</other_name>
    <other_name>TGR-1202</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed diffuse large B-cell lymphoma (DLBCL) or transformed DLBCL&#xD;
&#xD;
          -  Hematoxylin and eosin (H&amp;E) stain and immunohistochemistry (IHC) slides or a&#xD;
             representative formalin-fixed, paraffin-embedded (FFPE) tissue block along with the&#xD;
             pathology report from initial diagnosis, (as well as, an optional 8 unstained slides&#xD;
             of 4 micron thickness to store for future IHC and DNA specified research use), should&#xD;
             be sent to be reviewed, and the diagnosis confirmed by University of Nebraska Medical&#xD;
             Center (UNMC) (retrospective diagnostic review: treatment may commence prior to the&#xD;
             UNMC review); please NOTE: the diagnostic H&amp;E slide and IHC slides will be returned&#xD;
             after review; only the optional 8 unstained slides will be retained and stored for&#xD;
             future unspecified research use&#xD;
&#xD;
          -  Patients with relapsed or refractory DLBCL that has relapsed post-transplant or that&#xD;
             has been determined to be ineligible or unsuitable for transplant; patients must have&#xD;
             to have received at least one prior systemic therapy&#xD;
&#xD;
          -  Patients must have measurable (&gt;= 1.5 cm) or evaluable disease; baseline measurements&#xD;
             and evaluations must be obtained within 6 weeks of registration to the study; abnormal&#xD;
             PET scans will not constitute evaluable disease, unless verified by CT scan or other&#xD;
             appropriate imaging; measurable disease must have at least one objective measurable&#xD;
             disease parameter; a clearly defined, bi-dimensionally measurable defect or mass&#xD;
             measuring at least 1.5 cm in diameter on a CT scan will constitute measurable disease;&#xD;
             proof of lymphoma in the liver is required by a confirmation biopsy; skin lesions can&#xD;
             be used as measurable disease provided bi-dimensional measurements are possible&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1.0 x 10^9/L&#xD;
&#xD;
               -  By automated or manual review, whichever is greatest&#xD;
&#xD;
          -  Platelets &gt;= 100 x 10^9/L:&#xD;
&#xD;
               -  Unless due to bone marrow infiltration then eligible if platelets &gt; 50 x 10^9/L)&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 x upper normal limit if documented hepatic involvement with&#xD;
             lymphoma, or =&lt; 5 x upper normal limit if history of Gilbert's disease&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =&lt; 2.5 x upper&#xD;
             limit of normal (ULN) if no liver involvement or =&lt; 5 x the ULN if documented liver&#xD;
             involvement&#xD;
&#xD;
          -  Creatinine =&lt; 2.0 mg/dL OR calculated creatinine clearance &gt;= 50 mL/min (as calculated&#xD;
             by the Cockcroft-Gault method)&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 2 or expected survival&#xD;
             duration of &gt; 2 months&#xD;
&#xD;
          -  Ability to swallow and retain oral medication&#xD;
&#xD;
          -  Women must not be pregnant or breast-feeding&#xD;
&#xD;
               -  All female patients of child-bearing potential must have a negative serum&#xD;
                  pregnancy test within 2 weeks prior to treatment to rule out pregnancy&#xD;
&#xD;
               -  Pregnancy testing is not required for post-menopausal or surgically sterilized&#xD;
                  women&#xD;
&#xD;
          -  Male and female patients of reproductive potential must agree to follow accepted birth&#xD;
             control measures throughout the study period and for 30 days after the last dose of&#xD;
             either study drug for females and 3 months after the last dose of study drug for males&#xD;
&#xD;
          -  Patient must be able to adhere to the study visit schedule and other protocol&#xD;
             requirements&#xD;
&#xD;
          -  Patient must be aware of the neoplastic nature of his/her disease and willingly sign&#xD;
             (or their legally-acceptable representatives must sign) an informed consent document&#xD;
             indicating that they understand the purpose of and procedures required for the study,&#xD;
             including biomarkers, and are willing to participate in the study&#xD;
&#xD;
          -  No serious disease or condition that, in the opinion of the investigator, would&#xD;
             compromise the patient's ability to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently receiving cancer therapy (i.e., chemotherapy, radiation therapy,&#xD;
             immunotherapy, biologic therapy, hormonal therapy, and surgery and/or tumor&#xD;
             embolization) or any investigational drug within 7 days of cycle 1/day 1, 14 days of&#xD;
             cycle 1/day 1 for limited palliative radiation, and/or five half-live of an oral&#xD;
             therapy&#xD;
&#xD;
               -  Corticosteroid therapy started at least 7 days prior to initiation of treatment&#xD;
                  (prednisone =&lt; 10 mg daily or equivalent) is allowed as clinically warranted);&#xD;
                  topical or inhaled corticosteroids are permitted&#xD;
&#xD;
          -  Major surgery or a wound that has not fully healed within 4 weeks of enrollment&#xD;
&#xD;
          -  History of stroke or intracranial hemorrhage within 6 months prior to enrollment&#xD;
&#xD;
          -  Requires anticoagulation with warfarin or equivalent vitamin K antagonists (eg,&#xD;
             phenprocoumon)&#xD;
&#xD;
          -  Vaccinated with live, attenuated vaccines within 4 weeks of enrollment&#xD;
&#xD;
          -  Autologous hematologic stem cell transplant within 3 months of study entry&#xD;
&#xD;
          -  Allogeneic hematologic stem cell transplant within 12 months of study entry&#xD;
&#xD;
          -  Active graft versus-host disease and must not be on immunosuppression&#xD;
&#xD;
          -  Wide field radiotherapy within 28 days of cycle 1/day 1 or active side effects of such&#xD;
             therapy&#xD;
&#xD;
          -  Active hepatitis B (hepatitis B virus [HBV]) or C (hepatitis C virus [HCV]) infection&#xD;
             (negative serology required excluding those with are seropositive due to prior&#xD;
             vaccination) and/or known history of human immunodeficiency virus (HIV)&#xD;
&#xD;
          -  Primary central nervous system involvement only&#xD;
&#xD;
          -  Require treatment with strong cytochrome P450 family 3 subfamily A (CYP3A) inhibitors&#xD;
&#xD;
          -  Known history of drug-induced liver injury, alcoholic liver disease, primary biliary&#xD;
             cirrhosis, ongoing extra-hepatic obstruction caused by stones, cirrhosis of the liver&#xD;
             or portal hypertension&#xD;
&#xD;
          -  Any life-threatening illness, severe and/or uncontrolled medical condition, or organ&#xD;
             system dysfunction, laboratory abnormality, psychiatric illness or other condition&#xD;
             which, in the Investigator's opinion, could compromise the subject's safety, interfere&#xD;
             with the absorption or metabolism of ibrutinib capsules, put the study outcomes at&#xD;
             undue risk or affect their participation in the study such as&#xD;
&#xD;
               -  Symptomatic, or history of documented congestive heart failure New York Heart&#xD;
                  Association (NYHA) functional classification III-IV (NYHA)&#xD;
&#xD;
               -  Corrected QT interval using Fridericia's formula (QTcF) &gt; 470 msec (unless&#xD;
                  related to pacemaker) on echocardiogram (EKG) within 7 days of initiation of&#xD;
                  treatment&#xD;
&#xD;
               -  Angina not well-controlled by medication&#xD;
&#xD;
               -  Poorly controlled or clinically significant atherosclerotic vascular disease&#xD;
                  including cerebrovascular accident (CVA), transient ischemic attack (TIA),&#xD;
                  angioplasty, cardiac or vascular stenting within 6 months prior to enrollment&#xD;
&#xD;
          -  Prior malignancies within the past 1 year with exception of adequately treated basal&#xD;
             cell, squamous cell skin cancer, or thyroid cancer; carcinoma in situ of the cervix or&#xD;
             breast; prostate cancer of Gleason grade 6 or less with stable prostate specific&#xD;
             antigen (PSA) levels&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding; women who agree to stop breastfeeding would&#xD;
             be eligible&#xD;
&#xD;
          -  Known hypersensitivity to either study drug (TGR-1202 or ibrutinib)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew Lunning</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nebraska</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>August 17, 2016</study_first_submitted>
  <study_first_submitted_qc>August 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2016</study_first_posted>
  <results_first_submitted>January 30, 2020</results_first_submitted>
  <results_first_submitted_qc>February 12, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 26, 2020</results_first_posted>
  <last_update_submitted>February 12, 2020</last_update_submitted>
  <last_update_submitted_qc>February 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Nebraska</investigator_affiliation>
    <investigator_full_name>Matthew Lunning, DO</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 7, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/04/NCT02874404/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 25, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/04/NCT02874404/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were statified to Arms A, B, or C for correlative sample collection purposes only. Clinical study outcomes are not viewed differently among the groups, so subjects are presented as one arm/group.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>All Subjects</title>
          <description>Patients receive PI3K delta inhibitor TGR-1202 PO QD and ibrutinib PO QD on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Subjects</title>
          <description>Patients then receive PI3K delta inhibitor TGR-1202 PO QD and ibrutinib PO QD on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.5" spread="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Adverse Events Assessed Using NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03</title>
        <description>Notable serious or recurrent adverse events (SAEs or AEs) of interest occurring across all cycles regardless of attribution</description>
        <time_frame>Up to 112 days (course 4)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Subjects</title>
            <description>Patients receive PI3K delta inhibitor TGR-1202 PO QD on days 1-28 and ibrutinib PO QD on days 9-28 of course 1 and days 1-28 of subsequent courses. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Adverse Events Assessed Using NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03</title>
          <description>Notable serious or recurrent adverse events (SAEs or AEs) of interest occurring across all cycles regardless of attribution</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>G 3-4 elevated AST/ALT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G 3-4 nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G 3-4 diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response Rate (ORR)</title>
        <description>ORR is defined as number of patients achieving a best response of complete response or partial response at any disease assessment time point. Response is based on PET/CT (Deauville 3 or less) or CT alone if CR is achieved by PET/CT. Response criteria, modified from the Lugano response criteria. DLBCL is considered FDG avid.&#xD;
Complete response:&#xD;
Complete disappearance of all detectable clinical evidence of disease and definitely disease-related symptoms if present before therapy.&#xD;
Criteria for Partial Response (PR):&#xD;
Regression of measurable disease and no new sites</description>
        <time_frame>Up to 4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Patients</title>
            <description>Patients receive PI3K delta inhibitor TGR-1202 PO QD on days 1-28 and ibrutinib PO QD on days 9-28 of course 1 and days 1-28 of subsequent courses. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate (ORR)</title>
          <description>ORR is defined as number of patients achieving a best response of complete response or partial response at any disease assessment time point. Response is based on PET/CT (Deauville 3 or less) or CT alone if CR is achieved by PET/CT. Response criteria, modified from the Lugano response criteria. DLBCL is considered FDG avid.&#xD;
Complete response:&#xD;
Complete disappearance of all detectable clinical evidence of disease and definitely disease-related symptoms if present before therapy.&#xD;
Criteria for Partial Response (PR):&#xD;
Regression of measurable disease and no new sites</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Progression-free Survival (PFS) at 6 Months</title>
        <description>PFS is defined as the time between study registration and documented progression or death if no progression was observed.</description>
        <time_frame>Time between study registration and documented progression or death if no progression was observed, assessed up to 4 years (6 Month estimate shown)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Patients</title>
            <description>Patients receive PI3K delta inhibitor TGR-1202 PO QD on days 1-28 and ibrutinib PO QD on days 9-28 of course 1 and days 1-28 of subsequent courses. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Progression-free Survival (PFS) at 6 Months</title>
          <description>PFS is defined as the time between study registration and documented progression or death if no progression was observed.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="0.5" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Event reporting is only for TGR 1202 and Ibrutinib &quot;study medications,&quot; until 30 days after last administration of study medication. ( approximately 13 months)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>All Patients</title>
          <description>Patients receive PI3K delta inhibitor TGR-1202 PO QD on days 1-28 and ibrutinib PO QD on days 9-28 of course 1 and days 1-28 of subsequent courses. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>sinus tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>edema limbs</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>general disorders, other</sub_title>
                <description>weakness</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations, Other</sub_title>
                <description>diptheroid contaminant</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Infections and infestations, Other</sub_title>
                <description>clostridium difficile colitis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>enterocolitis infectious</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hypercalcemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>dehydration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>muscle weakness, general</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>confusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>pleural effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Other, infected port</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>dysphagia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>chills</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>upper respiratory infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Infections and infestations, Other</sub_title>
                <description>clostridium difficile colitis</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>platelet count decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Other, decreased appetite</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>hyperkalemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>hypokalemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Other, left shoulder pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>sore throat</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Other, skin rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Matthew Lunning, DO, Associate Professor</name_or_title>
      <organization>University of Nebraska Medical Center</organization>
      <phone>402-559-7164</phone>
      <email>mlunning@unmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

